AstraZeneca's selumetinib stumbles in Phase III
One of AstraZeneca's key prospects in oncology, selumetinib, has failed in at the Phase III stage in one of its potential indications, uveal melanoma.
One of AstraZeneca's key prospects in oncology, selumetinib, has failed in at the Phase III stage in one of its potential indications, uveal melanoma.